Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.

Neuro-oncology - 1 Sept 2022

Mohamed Esraa, Kumar Anupam, Zhang Yalan, Wang Albert S, Chen Katharine, Lim Yunita, Shai Anny, Taylor Jennie W, Clarke Jennifer, Hilz Stephanie, Berger Mitchel S, Solomon David A, Costello Joseph F, Molinaro Annette M, Phillips Joanna J

Abstract excerpt

BACKGROUND: IDH-mutant diffuse gliomas are heterogeneous, and improved methods for optimal patient therapeutic stratification are needed. PI3K/AKT/mTOR signaling activity can drive disease progression and potential therapeutic inhibitors of the pathway are available. Yet, the prevalence of PI3K/AKT/mTOR signaling pathway activity in IDH-mutant glioma is unclear and few robust strategies to assess activity in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Phosphatidylinositol 3-Kinases

Share to Proteomics

Share to Proto-Oncogene Proteins c-akt

Share to Signal Transduction

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 35287169
DOI: 10.1093/neuonc/noac064
PMCID: PMC9435510

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.PMID 35287169Read ↗

Integrative cBioPortal Analysis Revealed Molecular Mechanisms That Regulate EGFR-PI3K-AKT-mTOR Pathway in Diffuse Gliomas of the BrainSemantic proximity Read ↗

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.Semantic proximity Read ↗

Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma modelsSemantic proximity Read ↗

Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.Semantic proximity Read ↗

Role of RIPK1 in Diffuse Gliomas pathologySemantic proximity Read ↗

Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.Semantic proximity Read ↗

PIK3CA Mutations: Are They a Relevant Target in Adult Diffuse Gliomas?Semantic proximity Read ↗

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine gliomaSemantic proximity Read ↗

An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline gliomaSemantic proximity Read ↗

PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcomeSemantic proximity Read ↗

BRAF gene alterations and enhanced mammalian target of rapamycin signaling in gangliogliomas.Semantic proximity Read ↗

Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.